News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pevion Biotech Ltd.'s PEV7 Vulvovaginal Candidiasis Vaccine Enters Phase I


3/22/2010 9:32:23 AM

BERN, Switzerland--(BUSINESS WIRE)--Pevion Biotech, the Swiss vaccine company, today announced that PEV7, the first vaccine for chronic recurrent thrush - recurrent vulvovaginal candidiasis (VVC) has entered Phase 1 clinical trial. PEV7 aims to provide relief for an estimated 3-6 % of women worldwide who suffer from this largely unrecognized but highly debilitating condition. PEV7 has already proven to be effective in clearing the infection and preventing recurrence in animal models, and first results from the Phase I trial are expected later this year. PEV7 is based on Pevion Biotech's proprietary virosome delivery technology in which antigens bind to the surface of a "hollowed-out" virus-like particle (VLP).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES